

Anexo 4. Abreviaturas

APA	American Psychiatric Association
AVD	Actividades de la vida diaria
DSM-IV-TR	Diagnostic and Statistical Manual of Mental Disorders
DUP	Duración de la psicosis no tratada
EAAA	Efectos adversos de los antipsicóticos atípicos
ECA	Ensayo clínico aleatorizado
GAS	Global Assessment Scale
GC	Gestión de casos
GPC	Guía de Práctica Clínica
GPT	Guía de Prescripción Terapéutica
ICD-10	Classification of Mental and Behavioural Disorders
ISRS	Inhibidores selectivos de la recaptación de serotonina
IF	Intervención familiar
PORT	The schizophrenia patient outcomes research team
RSEC	Revisión sistemática de la evidencia científica
TAC	Tratamiento asertivo comunitario
TCC	Terapia cognitivo-conductual
TEC	Terapia electroconvulsiva
WFSBP	World Federation of Societies of Biological Psychiatry

Bibliografía

1. Ey H. *Traité des hallucinations*. Paris (France): Masson; 1973.
2. Yung AR, Yuen HP, McGorry PD, Phillips LJ, et al. Mapping the onset of Psychosis: The Comprehensive Assessment of At Risk Mental States. *Austr New Zealand J of Psychiat*. 2005;39(11-12):964-71.
3. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. *Schizophr Res*. 2003;61(1):7-18.
4. Yung AR, McGorry PD. The prodromal phase of first episode psychosis: Past and current conceptualisations. *Schizo Bulletin*. 1996;22: 353-70.
5. Yung AR, Phillips LJ, McGorry PD, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizo Research*. 2003;67:131-42.
6. Screening and treatment of adolescents with schizophrenia. The Hague (The Netherlands): Health Council of the Netherlands; 1999. Informe Núm. 1999/08E.
7. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry*. 1997;154 (4 Suppl):1-63.
8. Vázquez-Barquero JL, Cuesta Núñez MJ, de I, V, Herrera CS, Gaité L, Arenal A. The Cantabria first episode schizophrenia study: a summary of general findings. *Acta Psychiatr Scand*. 1995;91(3):156-62.
9. Murray RM. Epidemiological evidence concerning the diagnostic status of schizophrenia and bipolar disorder epidemiological [abstract of the XX International Congress on Schizophrenia Research]. *Schizophr Bull*. 2007;33(2):243.
10. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychol Med Monogr Suppl*. 1992;20:1-97.
11. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidente os schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. *Psychol Med*. 1986;16:909-28.

12. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. *Acta Psychiatr Scand.* 2005;111(1):4-11.
13. McGrath JJ. Variations. *Schizophr Bull.* 2006;32(1):195-7.
14. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. *BMC Med.* 2004;2:13.
15. Kirkbride JB, Fearon P, Morgan C, Dazzan P, Morgan K, Tarrant J, et al. Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes - Findings from the 3 center AESOP study. *Arch Gen Psychiatry.* 2006;63(3):250-8.
16. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med.* 2005;2(5):413-33.
17. Baldwin P, Browne D, Scully PJ, Quinn JF, Morgan MG, Kinsella A, et al. Epidemiology of first-episode psychosis: illustrating the challenges across diagnostic boundaries through the Cavan-Monaghan study at 8 years. *Schizophr Bull.* 2005;31(3):624-38.
18. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. *Pharmacoepidemiol Drug Saf.* 2006;15(12):873-9.
19. McEvoy JP, Scheifler PL, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. *J Clin Psychiatry.* 1999;60(Suppl 11):3-80.
20. Chinchilla Moreno A. Guía terapéutica de las esquizofrenias. Barcelona: Editorial Masson; 2000.
21. Practice guideline for the treatment of patients with schizophrenia [monografía en Internet]. American Psychiatric Association; 2004 [citado 2006]. Disponible en: http://www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf
22. Consenso español sobre evaluación y tratamiento de la esquizofrenia. Madrid: Sociedad Española de Psiquiatría; 1998.
23. Falloon IR, Montero I, Sungur M, Mastroeni A, Malm U, Economou M, et al. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. *World Psychiatry.* 2004;3(2):104-9.
24. National Collaborating Centre for Mental Health. Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. London (United Kingdom): The Royal College of Psychiatrists & The British Psychological Society. National Institut for Clinical Excellence; 2003.

25. McGorry P, Parkville V, Killackey E, Elkins K, Lambert M. Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). *Australas Psychiatry*. 2003;11(2):136-47.
26. Clinical practice guidelines. Treatment of schizophrenia. *Can J Psychiatry*. 2005;50(13 Suppl 1):7S-57S.
27. GPT 1. Guía de prescripción terapéutica. Información de medicamentos autorizados en España. Barcelona: Agencia española de medicamentos y productos sanitarios. Pharma Editores SL; 2006.
28. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry*. 1988;45(1):79-91.
29. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Møller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry*. 2006;7(1):5-40.
30. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Møller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. *World J Biol Psychiatry*. 2005;6(3):132-91.
31. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. *Schizophr Bull*. 2004;30(2):193-217.
32. Soler P, Gascón J. RTM III. Recomendaciones terapéuticas en los trastornos mentales. Comité de consenso de Catalunya en terapéutica de los trastornos mentales. 3a ed. Barcelona: Ars Medica; 2005.
33. Chinchilla Moreno A. Las esquizofrenias. Barcelona: Elsevier Masson; 2007.
34. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. *Schizophr Res*. 1991;4(2):109-20.
35. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. *JAMA*. 1961;175:1054-60.
36. Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, Lieberman JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. *Psychopharmacol Bull*. 1992;28(1):81-6.
37. Villegas I, López Román F, Martínez González A, Villegas J. Obesidad y síndrome metabólico en pacientes con esquizofrenia. *Psiquiatr Biol*. 2005;12(2):39-45.
38. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National

- Cholesterol Education Program Adult Treatment Panel III guidelines. *Arterioscler Thromb Vasc Biol.* 2004;24(8):e149-e161.
39. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. *J Clin Psychiatry.* 2005;66(4):504-14.
 40. Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. *Med J Aust.* 2004;181(10):544-8.
 41. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry.* 2006;18(3):183-94.
 42. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. *Schizophr Res.* 2004;71(2-3):195-212.
 43. Bellantuono C, Tentoni L, Donda P. Antipsychotic drugs and risk of type 2 diabetes: an evidence-based approach. *Hum Psychopharmacol.* 2004;19(8):549-58.
 44. Philippe A, Vaiva G, Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. *Eur Psychiatry.* 2005;20 Suppl 4:S340-S344.
 45. Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, Buse J. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. *Br J Psychiatry Suppl.* 2004;47:S94-101.
 46. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. *Br J Psychiatry Suppl.* 2004;47:S87-S93.
 47. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry.* 2004;161(8):1334-49.
 48. Perfil de toxicidad de los antipsicóticos atípicos. *Butlletí Groc (Fundació Institut Català de Farmacologia de la Universitat Autònoma de Barcelona).* 2002;15(1). Disponible en: <http://www.icf.uab.es/informacion/boletines/bg/bg151.02e.pdf>.
 49. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med.* 2009;360(3):225-35.
 50. Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. *Ann Clin Psychiatry.* 1995;7(3):139-41.
 51. Hatta K, Takahashi T, Nakamura H, Fujii S, Yamashiro H, Asukai N, et al. Prolonged upper airway instability in the parenteral use of benzodia-

- zepine with levomepromazine. *J Clin Psychopharmacol*. 2000;20(1):99-101.
52. APA Practice Guideline Development Process [monografía en Internet]. Arlington, VA (US): The American Psychiatric Association (APA). Disponible en: <http://www.psych.org>
 53. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *Aust N Z J Psychiatry*. 2005;39(1-2):1-30.
 54. Rojo Rodés JE, Vallejo Ruiloba J. *Terapia electroconvulsiva*. Barcelona: Masson-Salvat; 1994.
 55. *La psicoterapia a la xarxa pública de Salut Mental y Adiccions* [documento de uso interno]. Barcelona; 2007.
 56. Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. *J Am Acad Psychoanal Dyn Psychiatry*. 2003;31(1):141-54.
 57. Gisbert C, coordinación. *Rehabilitación psicosocial del trastorno mental severo. Situación actual y recomendaciones*. Madrid: Asociación Española de Neuropsiquiatría (AEN); 2002. Cuaderno Técnicos núm. 6.
 58. *Consenso español de expertos para recomendaciones de actuación en el tratamiento de la esquizofrenia*. Madrid: Sociedad Española de Psiquiatría; 2000.
 59. *Strategies therapeutiques a long term dans les psychoses schizophréniques*. Paris (France): Fédération Française de Psychiatrie; 1994.
 60. Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C. Cognitive behaviour therapy for schizophrenia. *Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD000524. DOI: 10.1002/14651858.CD000524.pub2.
 61. Gaudiano BA. Is symptomatic improvement in clinical trials of cognitive-behavioral therapy for psychosis clinically significant? *J Psychiatr Pract*. 2006;12(1):11-23.
 62. Tarrrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? *Behav Res Ther*. 2004;42(12):1377-401.
 63. Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia. *J Nerv Ment Dis*. 2006;194(1):3-9.
 64. Penn DL, Mueser KT, Tarrrier N, Gloege A, Cather C, Serrano D, et al. Supportive therapy for schizophrenia: possible mechanisms and

- implications for adjunctive psychosocial treatments. *Schizophr Bull.* 2004;30(1):101-12.
65. Ávila Espada A, Poch Bullich J. Manual de técnicas de psicoterapia. Un enfoque psicoanalítico. Madrid: Siglo Veintiuno de España Editores, SA; 1994.
 66. Malmberg L, Fenton M. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness. *Cochrane Database of Systematic Reviews* 2001, Issue 3. Art. No.: CD001360. DOI: 10.1002/14651858.CD001360.
 67. Pekkala E, Merinder L. Psicoeducación para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
 68. Pharoah FM, Mari JJ, Streiner D. Family intervention for schizophrenia. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD000088. DOI: 10.1002/14651858.CD000088.pub2.
 69. Barbato A, D'Avanzo B. Family interventions in schizophrenia and related disorders: a critical review of clinical trials. *Acta Psychiatr Scand.* 2000;102(2):81-97.
 70. Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia - a meta-analysis. *Schizophr Bull.* 2001;27(1):73-92.
 71. Huxley NA, Rendall M, Sederer L. Psychosocial treatments in schizophrenia: a review of the past 20 years. *J Nerv Ment Dis.* 2000;188(4):187-201.
 72. Pharoah F, Mari J, Rathbone J, Wong W. Intervención familiar para la esquizofrenia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2007 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
 73. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. *Schizophr Bull.* 2006;32 Suppl 1:S64-S80.
 74. Butzlaff RL, Hooley JM. Expressed emotion and psychiatric relapse: a meta-analysis. *Arch Gen Psychiatry.* 1998;55(6):547-52.
 75. McFarlane WR, Dixon L, Lukens E, Lucksted A. Family psychoeducation and schizophrenia: a review of the literature. *J Marital Fam Ther.* 2003;29(2):223-45.

76. Bustillo JR, Lauriello J, Horan WP, Keith SJ. Actualización del tratamiento psicosocial de la esquizofrenia. *Am J Psychiatr (Ed Esp)*. 2001;4(2):104-16.
77. Sellwood W, Barrowclough C, TARRIER N, Quinn J, Mainwaring J, Lewis S. Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. *Acta Psychiatr Scand*. 2001;104(5):346-55.
78. Barrowclough C, TARRIER N, Lewis S, Sellwood W, Mainwaring J, Quinn J, et al. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia. *Br J Psychiatry*. 1999;174:505-11.
79. Panades R. La rehabilitación neuropsicológica del paciente esquizofrénico [tesis doctoral]. Barcelona: Universitat de Barcelona; 2002.
80. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia? *J Psychiatry Neurosci*. 2004;29(2):102-13.
81. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Pridhoda TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. *Am J Psychiatry*. 2000;157(8):1317-23.
82. McGurk SR, Twamley EW, Sitzler DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. *Am J Psychiatry*. 2007;164(12):1791-802.
83. Hayes RL, McGrath JJ. Cognitive rehabilitation for people with schizophrenia and related conditions. *Cochrane Database of Systematic Reviews* 2000, Issue 3. Art. No.: CD000968. DOI: 10.1002/14651858.CD000968.
84. Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. *Am J Psychiatry*. 1996;153(12):1585-92.
85. Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. *Am J Psychiatry*. 1998;155(8):1087-91.
86. National Collaborating Centre for Mental Health. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Draft for consultation [documento provisional]. London (United Kingdom): National Institute for Clinical Excellence; September 2008.
87. Modelo de Atención a personas con Enfermedad mental grave. Documento de consenso. Madrid: IMSERSO. Ministerio de Trabajo y Asuntos Sociales; 2006.

88. Drake RE, Mueser KT, Torrey WC, Miller AL, Lehman AF, Bond GR, et al. Evidence-based treatment of schizophrenia. *Curr Psychiatry Rep.* 2000;2(5):393-7.
89. Bond GR, Becker DR, Drake RE, Rapp CA, Meisler N, Lehman AF, et al. Implementing supported employment as an evidence-based practice. *Psychiatr Serv.* 2001;52(3):313-22.
90. Crowther R, Marshall M, Bond G, Huxley P. Rehabilitaci3n vocacional para personas con enfermedades mentales graves (Revisi3n Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 N3mero 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de *The Cochrane Library*, 2008 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).
91. Killackey EJ, Jackson HJ, Gleeson J, Hickie IB, McGorry PD. Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first-episode psychosis: employing cautious optimism. *Aust N Z J Psychiatry.* 2006;40(11-12):951-62.
92. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. *J Nerv Ment Dis.* 2003;191(8):515-23.
93. Lascorz D, Serrats E, P3rez V, F3bregas J, Vegu3 J. Estudio comparativo coste/eficacia de un dispositivo residencial para enfermos con trastorno mental severo. *Rev Asoc Esp Neuropsiquiatr.* 2009;103(1):191-201.
94. Burns T. *Community mental health teams. A guide to current practices.* New York, NY (US): Oxford University Press; 2005.
95. Malone D, Marriott S, Newton-Howes G, Simmonds S, Tyrer P. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personality. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD000270. DOI: 10.1002/14651858.CD000270.pub2.
96. Malm U, Ivarsson B, Allebeck P, Falloon IR. Integrated care in schizophrenia: a 2-year randomized controlled study of two community-based treatment programs. *Acta Psychiatr Scand.* 2003;107(6):415-23.
97. Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. Integrated treatment ameliorates negative symptoms in first episode psychosis--results from the Danish OPUS trial. *Schizophr Res.* 2005;79(1):95-105.
98. Killaspy H, Bebbington P, Blizard R, Johnson S, Nolan F, Pilling S, et al. The REACT study: randomised evaluation of assertive community treatment in north London. *BMJ.* 2006;332(7545):815-20.
99. Commander M, Sashidharan S, Rana T, Ratnayake T. North Birmingham assertive outreach evaluation. Patient characteristics and cli-

- nical outcomes. *Soc Psychiatry Psychiatr Epidemiol.* 2005;40(12):988-93.
100. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD001089. DOI: 10.1002/14651858.CD001089.
 101. Marshall M, Gray A, Lockwood A, Green R. Case management for people with severe mental disorders. *Cochrane Database of Systematic Reviews* 1998, Issue 2. Art. No.: CD000050. DOI: 10.1002/14651858.CD000050.
 102. Mueser KT, Bond GR, Drake RE, Resnick SG. Models of community care for severe mental illness: a review of research on case management. *Schizophr Bull.* 1998;24(1):37-74.
 103. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M. Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. *BMJ.* 2007;335(7615):336.
 104. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. *J Am Acad Child Adolesc Psychiatry.* 2001;40(7 Suppl):4S-23S.
 105. Carney CP, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. *J Gen Intern Med.* 2006;21(11):1133-7.
 106. Kelly M, Lamah M. Evaluating the accuracy of data entry in a regional colorectal cancer database: implications for national audit. *Colorectal Dis.* 2007;9(4):337-9.
 107. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *J Clin Psychiatry.* 2004;65(2):267-72.
 108. Consenso sobre promoción de la salud mental, prevención del trastorno mental y disminución del estigma de la Asociación Española de Neuropsiquiatría. Madrid: Asociación Española de Neuropsiquiatría; 2007.
 109. Enfermedad mental: análisis de las actitudes de rechazo social y estigmatización que sufren las personas con enfermedad mental. Madrid: Consejería de Asuntos Sociales de la Comunidad de Madrid; 2006.
 110. McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical interven-

- tion in prepsychotic mental disorder. *Schizophr Bull.* 2003;29(4):771-90.
111. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. *Arch Gen Psychiatry.* 2002;59(10):921-8.
 112. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. *Acta Psychiatr Scand.* 2006;113(4):247-72.
 113. Bechdolf A, Phillips LJ, Francey SM, Leicester S, Morrison AP, Veith V, et al. Recent approaches to psychological interventions for people at risk of psychosis. *Eur Arch Psychiatry Clin Neurosci.* 2006;256(3):159-73.
 114. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. *Eur Psychiatry.* 2005;20(5-6):372-8.
 115. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. *Schizophr Res.* 2004;67(2-3):131-42.
 116. Johannessen J, Martindale B, Culberg J. *Evolución de las psicosis.* Barcelona: Herder; 2008.
 117. Nordentoft M, Thorup A, Petersen L, Ohlenschlaeger J, Melau M, Christensen TO, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. *Schizophr Res.* 2006;83(1):29-40.
 118. Phillips LJ, Yung AR, Yuen HP, Pantelis C, McGorry PD. Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. *Am J Med Genet.* 2002;114(8):929-37.
 119. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. *Br J Psychiatry Suppl.* 2005;48:s116-s119.
 120. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. *Br J Psychiatry Suppl.* 2005;48(187):S120-S124.
 121. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? *Biol Psychiatry.* 1999;46(7):899-907.

122. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. *Am J Psychiatry*. 2005;162(12):2220-32.
123. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry*. 2003;160(8):1396-404.
124. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet*. 2008;371(9618):1085-97.
125. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry*. 2005;162(5):947-53.
126. Opjordsmoen S, Melle I, Friis S, Haahr U, Johannessen JO, Tor K, et al. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics. *Early Interv Psychiatry*. 2009;3(1):58-65.
127. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry*. 2007;164(7):1050-60.
128. Jeppesen P, Petersen L, Thorup A, Abel M, Ehlerschlger J, Christensen T, et al. Integrated treatment of first-episode: effect of treatment on family burden. *Br J Psychiatry*. 2005;187:S85-S90.
129. Garety PA, Craig TK, Dunn G, Fornells-Ambrojo M, Colbert S, Rahaman N, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction: randomised controlled trial. *Br J Psychiatry*. 2006;188:37-45.
130. Marshall M, Rathbone J. Early Intervention for psychosis. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD004718. DOI: 10.1002/14651858.CD004718.pub2.
131. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. *Br J Psychiatry Suppl*. 1998;172(33):53-9.
132. Edwards J, McGorry P. La intervención precoz en la psicosis: Guía para la creación de servicios de intervención precoz en la psicosis. Madrid: Editorial Fundación para el tratamiento de la esquizofrenia y otras psicosis; 2004.

133. Vishnu Gopal Y, Variend H. First-episode schizophrenia: review of cognitive deficits and cognitive remediation. *Adv Psychiatr Treat.* 2005;11:38-44.
134. Rinaldi M, McNeil K, Firm M, Koleti M, Perkins R. What are the benefits of evidence-based supported employment for patients with first-episode psychosis. *Psychiatr Bull.* 2004;28:281-4.
135. McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. *Schizophr Bull.* 1996;22(2):201-22.
136. Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston-Cronk K, Zimmermann K, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. *Am J Psychiatry.* 1992;149(11):1549-55.
137. Wallace CJ, Liberman RP, MacKain SJ, Blackwell G, Eckman TA. Effectiveness and replicability of modules for teaching social and instrumental skills to the severely mentally ill. *Am J Psychiatry.* 1992;149(5):654-8.
138. Eckman TA, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. *J Clin Psychopharmacol.* 1990;10(1):33-8.
139. Rector NA, Beck AT. Cognitive behavioral therapy for schizophrenia: an empirical review. *J Nerv Ment Dis.* 2001;189(5):278-87.
140. Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: Effects on adjustment of patients. *Am J Psychiatry.* 1997;154(11):1514-24.
141. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, et al. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: Description of study and effects on relapse rates. *Am J Psychiatry.* 1997;154(11):1504-13.
142. Psychosocial interventions in the management of schizophrenia. A national clinical guideline. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1998. SIGN publication núm. 30.
143. Crowther R, Marshall M, Bond G, Huxley P. Rehabilitaci3n vocacional para personas con enfermedades mentales graves (Revisi3n Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 N3mero 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de The Cochrane Library, 2008 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).

144. Martens WH. A review of physical and mental health in homeless persons. *Public Health Rev.* 2001;29(1):13-33.
145. Acute Pain Management Guideline Panel. Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Rockville, MD (US): Public Health Service. Department of Health and Human Services; 1992.
146. Hospital inpatient management of acute asthma attacks source. Edinburgh (United Kingdom): Scottish Intercollegiate Guidelines Network (SIGN); 1996. Report Number 6.



P.V.P.: 6 €